Mark DayGlobal Head, Genetic Diseases and Immuno-Virology. Bristol-Myers Squibb
Rajesh RanaganathanDirector, Office of Translational Research NIH
Rogerio VivaldiCo-Founder, President & CEO Minerva Neurosciences
Frank YoccaVice President, Neuroscience iMed AstraZeneca
The Translational CNS Summit 2014 delivers a unique opportunity to work collaboratively with your peers to bring safe and effective CNS therapies to patients in need. Maximize the value of your CNS pipeline by improving pre-clinical predictability that will de-risk your development and reduce late-stage attrition rates.
The meeting aims to facilitate collaboration and forward movement for the industry by bringing together the leading drug developers in this space. Attend and discover new ways to progress your pipeline and tap into the huge commercial opportunity CNS diseases represent.
Discover the technologies and techniques that are proving beneficial to drug development and avoid the approaches that have historically led to failure.
Attendees will meet with commercial and academic leaders to inspire new ideas and strategies to help minimize clinical attrition, maximise pipeline potential and see a return on investments made in the CNS field.
The agenda has been designed to promote interaction and audience engagement, with multiple opportunities to network, interact and discus via:
“Great organization, agenda, speaker panel, audience – I couldn’t have asked for anything more!” Scannexus
“The talks were high quality and the interaction among the participants was excellent” Genentech
“The conference was an excellent size where optimal discussion occurredand the presentations were of high quality” Envivo Pharma
“ Overall an excellent meeting. Thanks.” AMRI